Moleculin Biotech (MBRX) PT Raised to $18 at Oppenheimer

February 4, 2021 8:54 AM EST
Get Alerts MBRX Hot Sheet
Price: $3.44 -5.23%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Oppenheimer analyst Kevin DeGeeter raised the price target on Moleculin Biotech (NASDAQ: MBRX) to $18.00 (from $12.00) while maintaining an Outperform rating.

The analyst commented, "Our investment thesis for shares on MBRX has been based primarily on: 1) differentiated cardiovascular safety profile of annamycin compared to other anthracyclines; and 2) intriguing in vivo data suggesting elevated annamycin concentrations in lung might provide promise in treating lung metastasis - a setting where other anthracyclines have limited activity. Raising PT to $18 from post-split adjusted $12 based on data released this week demonstrating impressive survival benefit in preclinical model of osteosarcoma lung mets. Our new 2021 and 2022 EPS estimates are ($0.96) and ($1.06), respectively, reflecting 1-for-6 reserve stock split partially offset by dilution from recent $68M equity financing. We now believe MBRX may have sufficient cash balance to fund operations through to profitability."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change